NCT lookup
Pull any trial record directly from ClinicalTrials.gov.
Sponsor: Ahmad Shariftabrizi
Conditions: Triple Negative Breast Cancer
Interventions: PET imaging
Countries: United States
The purpose of this research is to determine the expression of Prostate Specific Membrane Antigen(PSMA) in metastatic Triple Negative Breast Cancer (TNBC) patients using Fludeoxyglucose F18 (FDG) PET/CT as the gold standard. The investigators hypothesize that most lesions in metastatic TNBC are PSMA-avid; and thus PSMA-based radionuclide therapy can be a valid treatment option for TNBC, and clinical trials can be designed for this purpose. Thirty metastatic TNBC patients will be enrolled and will be on the study for maximum of 4 weeks.
Sex: FEMALE
Age: 18 Years to 90 Years
Healthy volunteers: No
Study type: INTERVENTIONAL
Inclusion Criteria: * Female \>= 18 years of age * Patients in distantly metastatic TNBC based on the initial diagnosis biopsy. * Patient should have FDG positive metastatic lesions on the initial PET/CT scan performed in this study to be further included. Exclusion Criteria: * Patients with known active other malignancy. * Unable to tolerate PET/CT procedure. * Pregnant or breastfeeding. * Patients with any medical condition that might compromise the safety of subject during PET acquisitions.
- Iowa City, Iowa, United States